Annual Working Capital
$90.98 M
-$11.18 M-10.94%
31 December 2023
Summary:
Y-mAbs Therapeutics annual working capital is currently $90.98 million, with the most recent change of -$11.18 million (-10.94%) on 31 December 2023. During the last 3 years, it has fallen by -$11.85 million (-11.52%). YMAB annual working capital is now -54.13% below its all-time high of $198.37 million, reached on 31 December 2019.YMAB Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Working Capital
$73.77 M
-$9.53 M-11.44%
30 September 2024
Summary:
Y-mAbs Therapeutics quarterly working capital is currently $73.77 million, with the most recent change of -$9.53 million (-11.44%) on 30 September 2024. Over the past year, it has dropped by -$19.28 million (-20.72%). YMAB quarterly working capital is now -70.14% below its all-time high of $247.01 million, reached on 31 March 2021.YMAB Quarterly Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
YMAB Working Capital Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -10.9% | -20.7% |
| 3 y3 years | -11.5% | -64.1% |
| 5 y5 years | -36.1% | -13.8% |
YMAB Working Capital High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -47.8% | at low | -64.1% | at low |
| 5 y | 5 years | -54.1% | at low | -70.1% | at low |
| alltime | all time | -54.1% | +536.9% | -70.1% | +11.8% |
Y-mAbs Therapeutics Working Capital History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $73.77 M(-11.4%) |
| June 2024 | - | $83.29 M(-8.1%) |
| Mar 2024 | - | $90.66 M(-0.4%) |
| Dec 2023 | $90.98 M(-10.9%) | $90.98 M(-2.2%) |
| Sept 2023 | - | $93.05 M(+1.6%) |
| June 2023 | - | $91.55 M(-6.7%) |
| Mar 2023 | - | $98.09 M(-4.0%) |
| Dec 2022 | $102.16 M(-41.4%) | $102.16 M(+0.9%) |
| Sept 2022 | - | $101.23 M(-18.7%) |
| June 2022 | - | $124.47 M(-16.3%) |
| Mar 2022 | - | $148.70 M(-14.7%) |
| Dec 2021 | $174.39 M | $174.39 M(-15.0%) |
| Sept 2021 | - | $205.22 M(-10.1%) |
| June 2021 | - | $228.38 M(-7.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2021 | - | $247.01 M(+140.2%) |
| Dec 2020 | $102.83 M(-48.2%) | $102.83 M(-9.3%) |
| Sept 2020 | - | $113.43 M(-23.2%) |
| June 2020 | - | $147.61 M(-15.6%) |
| Mar 2020 | - | $174.99 M(-11.8%) |
| Dec 2019 | $198.37 M(+39.3%) | $198.37 M(+131.7%) |
| Sept 2019 | - | $85.60 M(-21.9%) |
| June 2019 | - | $109.56 M(-13.5%) |
| Mar 2019 | - | $126.73 M(-11.0%) |
| Dec 2018 | $142.41 M(+70.7%) | $142.41 M(-9.1%) |
| Sept 2018 | - | $156.73 M(+137.5%) |
| June 2018 | - | $66.00 M(-20.9%) |
| Dec 2017 | $83.43 M(+484.0%) | $83.43 M |
| Dec 2016 | $14.29 M | - |
FAQ
- What is Y-mAbs Therapeutics annual working capital?
- What is the all time high annual working capital for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics annual working capital year-on-year change?
- What is Y-mAbs Therapeutics quarterly working capital?
- What is the all time high quarterly working capital for Y-mAbs Therapeutics?
- What is Y-mAbs Therapeutics quarterly working capital year-on-year change?
What is Y-mAbs Therapeutics annual working capital?
The current annual working capital of YMAB is $90.98 M
What is the all time high annual working capital for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high annual working capital is $198.37 M
What is Y-mAbs Therapeutics annual working capital year-on-year change?
Over the past year, YMAB annual working capital has changed by -$11.18 M (-10.94%)
What is Y-mAbs Therapeutics quarterly working capital?
The current quarterly working capital of YMAB is $73.77 M
What is the all time high quarterly working capital for Y-mAbs Therapeutics?
Y-mAbs Therapeutics all-time high quarterly working capital is $247.01 M
What is Y-mAbs Therapeutics quarterly working capital year-on-year change?
Over the past year, YMAB quarterly working capital has changed by -$19.28 M (-20.72%)